Genix Pharmaceuticals Corporation (TSXV:GENX)
Canada · Delayed Price · Currency is CAD 0.0200
0.00 (0.00%)
At close: Aug 21, 2026
Genix Pharmaceuticals Balance Sheet
Financials in millions CAD. Fiscal year is November - October.
Millions CAD. Fiscal year is Nov - Oct.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 30, 2026 | Oct '25 Oct 31, 2025 | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 |
Cash & Equivalents | 0.01 | 0.04 | 0.01 | 0.01 | 0.01 | 0.14 |
Cash & Short-Term Investments | 0.01 | 0.04 | 0.01 | 0.01 | 0.01 | 0.14 |
Cash Growth | 161.68% | 279.69% | -1.30% | 25.51% | -93.32% | -80.07% |
Other Receivables | 0 | 0 | 0.01 | 0 | 0.02 | 0 |
Receivables | 0 | 0 | 0.01 | 0 | 0.02 | 0 |
Inventory | - | - | - | 0.16 | 0.17 | 0 |
Prepaid Expenses | 0.02 | 0.01 | 0.02 | 0.04 | 0.04 | 0.04 |
Total Current Assets | 0.03 | 0.05 | 0.04 | 0.22 | 0.24 | 0.19 |
Property, Plant & Equipment | - | - | - | - | 0 | 0.03 |
Other Intangible Assets | 0 | 0 | 0.01 | 0.01 | 4.01 | 4.55 |
Total Assets | 0.03 | 0.05 | 0.05 | 0.22 | 4.25 | 4.77 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 30, 2026 | Oct '25 Oct 31, 2025 | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 |
Accounts Payable | 0.18 | 0.16 | 0.15 | 0.25 | 0.21 | 0.01 |
Accrued Expenses | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 |
Short-Term Debt | 1.15 | 1.04 | 0.82 | 0.51 | 0.18 | 0.02 |
Current Portion of Leases | - | - | - | - | 0 | 0.02 |
Other Current Liabilities | 0.24 | 0.25 | 0.24 | 0.58 | 0.64 | 0.66 |
Total Current Liabilities | 1.58 | 1.47 | 1.23 | 1.36 | 1.05 | 0.74 |
Long-Term Leases | - | - | - | - | - | 0.01 |
Total Liabilities | 1.58 | 1.47 | 1.23 | 1.36 | 1.05 | 0.76 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 30, 2026 | Oct '25 Oct 31, 2025 | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 |
Common Stock | 9.76 | 9.76 | 9.7 | 9.7 | 9.7 | 9.7 |
Retained Earnings | -12.67 | -12.54 | -12.2 | -12.13 | -7.74 | -6.66 |
Comprehensive Income & Other | 1.36 | 1.36 | 1.32 | 1.29 | 1.23 | 0.97 |
Shareholders' Equity | -1.55 | -1.42 | -1.18 | -1.14 | 3.2 | 4.01 |
Total Liabilities & Equity | 0.03 | 0.05 | 0.05 | 0.22 | 4.25 | 4.77 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 30, 2026 | Oct '25 Oct 31, 2025 | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 |
Total Debt | 1.15 | 1.04 | 0.82 | 0.51 | 0.18 | 0.05 |
Net Cash (Debt) | -1.14 | -1 | -0.8 | -0.5 | -0.17 | 0.09 |
Net Cash Growth | - | - | - | - | - | -86.81% |
Net Cash Per Share | -0.02 | -0.02 | -0.01 | -0.01 | -0.00 | 0.00 |
Filing Date Shares Outstanding | 61.22 | 61.22 | 59.22 | 59.22 | 59.22 | 59.22 |
Total Common Shares Outstanding | 61.22 | 61.22 | 59.22 | 59.22 | 59.22 | 59.22 |
Working Capital | -1.55 | -1.42 | -1.19 | -1.15 | -0.81 | -0.56 |
Book Value Per Share | -0.03 | -0.02 | -0.02 | -0.02 | 0.05 | 0.07 |
Tangible Book Value | -1.55 | -1.42 | -1.19 | -1.15 | -0.81 | -0.53 |
Tangible Book Value Per Share | -0.03 | -0.02 | -0.02 | -0.02 | -0.01 | -0.01 |